By evaluating the levels of key systemic inflammatory markers, such as CRP, ESR, NLR, and PLR in osteosarcoma patients, we seek to elucidate their potential role as predictive biomarkers for metastatic disease. The gene discussed is ESR1; the disease is osteosarcoma.